Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21590671 | 0.86 | USP2 (0.37) | USP2SMN1; SMN2HPGDEPHX2POLB | |
| SCHEMBL13661298 | 0.84 | USP2 (0.45) | USP2SMN1; SMN2TACR1OPRD1OPRK1 | |
| SCHEMBL25845775 | 0.81 | USP2 (0.47) | USP2SMN1; SMN2TACR1OPRD1OPRK1 | |
| SCHEMBL1086226 | 0.81 | USP2 (0.47) | USP2SMN1; SMN2TACR1OPRD1OPRK1 | |
| SCHEMBL849402 | 0.79 | USP2 (0.49) | USP2SMN1; SMN2TACR1HPGDGPR119 | |
| SCHEMBL24752804 | 0.78 | USP2 (0.45) | USP2SMN1; SMN2HPGDEPHX2NAMPT | |
| SCHEMBL2945193 | 0.77 | USP2 (0.50) | USP2SMN1; SMN2TACR1HPGDGPR119 | |
| SCHEMBL2349423 | 0.77 | USP2 (0.50) | USP2SMN1; SMN2TACR1HPGDGPR119 | |
| SCHEMBL16049599 | 0.77 | USP2 (0.44) | USP2SMN1; SMN2TACR1HPGDEPHX2 | |
| SCHEMBL15286297 | 0.77 | USP2 (0.41) | USP2SMN1; SMN2TACR1GPR119EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970189-B1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS INC (US) | 2020-05-06 | — | — | EP | disclosed |
| EP-2970189-B1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-9365545-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365545-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160046579-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC | 2016-02-18 | — | — | US | disclosed |
| EP-2970189-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Agios Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150336931-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC | 2015-11-26 | — | — | US | disclosed |
| US-20150336931-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC | 2015-11-26 | — | — | US | disclosed |
| US-9108921-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108921-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC (US) | 2015-08-18 | — | — | US | disclosed |
| US-20140288081-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288081-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC (US) | 2014-09-25 | — | — | US | disclosed |
| WO-2014139144-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014139144-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014139325-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014139325-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046579-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PC, PDK2 | USP2 4223/4885SMN1; SMN2 1969/4885TACR1 3874/4885 |
| US-20140288081-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PC, PDK2 | USP2 4238/4885SMN1; SMN2 1852/4885TACR1 4178/4885 |
| US-20150336931-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PC, PDK2 | USP2 4238/4885SMN1; SMN2 1852/4885TACR1 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.